2020
- 06Received Orphan Drug Designation from FDA for NT-I7 in the treatment of Progressive Multifocal Leukoencephalopathy
- 04Announced a clinical collaboration with Bristol Myers Squibb (BMS) for NT-I7/Nivolumab combinations
2019
- 08NeoImmuneTech Co., Ltd., a wholly owned subsidiary of NIT, was established in Aug 2019 (and the liaison office in Korea was subsequently closed out in October 2019)
- 04Received Orphan Drug Designation from FDA for NT-I7 in the treatment of Idiopathic CD4 lymphocytopenia
- 01First U.S. Glioblastoma (non-lymphopenia) Patient Treatment with NT-I7 in Phase 1b/2a study
Received Phase 1b/2a IND Approval from FDA for NT-I7 and TECENTRIQ® (Roche) targeting Advanced High-Risk Skin Cancers
2018
-
12
First U.S. Glioblastoma (lymphopenia) Patient Treatment with NT-I7 in Phase 1b/2a study
Received Phase 1b/2a IND Approval from MFDS for NT-I7 and KEYTRUDA® (Merck) targeting Triple Negative Breast Cancers (TNBC)
-
11
Received FDA IND Approval for Treatment of NT-I7 targeting Glioblastoma (non-lymphopenia) for Phase 1b/2a
-
07
Announced Clinical Trial Collaboration with Merck and Genexine for NT-I7 and KEYTRUDA® (Merck) targeting
Triple Negative Brest Cancer (TNBC)
-
05
Announced Clinical Trial Collaboration of NT-I7 and TECENTRIQ® (Roche) targeting Advanced High-Risk
Skin Cancers
Established liaison office in Korea (670, Daewangpangyo-ro, Bundang-gu, Uspace2 B 501-1 Seongnam-si, Gyeonggi-do, Republic of Korea 13494)
-
03
Received Phase 1b/2a IND Approval from FDA for NT-I7 targeting Glioblastoma (lymphopenia)
2017
- 10Headquarters Relocated and Expanded to 2400 Research Boulevard, Rockville, MD 20850
- 05Received Orphan Drug Designation from EMA for NT-I7 in the treatment of Idiopathic CD4 lymphocytopenia
2015
- 06Received development and commercialization rights of NT-I7 (efineptakin alfa, rhIL-7-hyFc) from Genexine in America and Europe
2014
- 10Headquarters Relocated to 2200 Research Blvd., Rockville, MD 20850.
- 01NeoImmuneTech, Inc. Founded at 20271 Goldenrod Lane Germantown, MD 20876